<div id="readability-page-1"><p>Wells Fargo analyst Benjamin Burnett maintained a Buy rating on Keros Therapeutics yesterday and set a price target of $23.00.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>According to TipRanks, Burnett is an analyst with an average return of <span>-3.0%</span> and a 40.50% success rate. Burnett covers the Healthcare sector, focusing on stocks such as Alkermes, Xenon, and MannKind.</p> <p>Keros Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $21.00.</p></div>

KROS

<p>Wells Fargo analyst Benjamin Burnett maintains a Buy rating on Keros Therapeutics, setting a price target of $23.00. Burnett, who covers the Healthcare sector, has an average return of -3.0% and a 40.50% success rate. Keros Therapeutics holds a Moderate Buy consensus with a price target of $21.00.</p>

Wells Fargo Remains a Buy on Keros Therapeutics (KROS)